Physician profile
David R Katzen
NPI 1093711830
$4,655.28
in general payments reported to CMS, 2019-2025
20 companies · $30.64 in 2025
The $30.64 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $688 · 2021: $696 · 2022: $932 · 2023: $818 · 2024: $711 · 2025: $30.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,292.58 | 2019-2024 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $952.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $488.03 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $440.70 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $293.58 | 2019-2021 | |
| Kaleo, INC. | $241.49 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $220.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $178.08 | 2019-2022 | |
| Amgen INC. | $110.81 | 2021-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.30 | 2020-2022 | |
| Blueprint Medicines Corporation | $90.62 | 2023 | Ayvakit |
| Optinose US, INC. | $48.86 | 2021-2022 | |
| Abbvie INC. | $46.94 | 2022-2023 | |
| Covis Pharma Gmbh | $36.58 | 2021 | |
| Pfizer INC. | $29.85 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $24.68 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $17.47 | 2021 | |
| Incyte Corporation | $16.22 | 2022 | |
| Leo Pharma INC. | $14.80 | 2022 | |
| Philips North America LLC | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Katzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.